

Multimodal Gadolinium-Enriched DNA–Gold Nanoparticle Conjugates for Cellular Imaging**

Ying Song, Xiaoyang Xu, Keith W. MacRenaris, Xue-Qing Zhang, Chad A. Mirkin,* and Thomas J. Meade*

During the past two decades, magnetic resonance imaging (MRI) has become a powerful technique in clinical diagnosis and biological molecular imaging.^[1–4] A significant advantage of MRI is the ability to acquire tomographic information of whole animals with high spatial resolution and soft tissue contrast. In addition, images are acquired without the use of ionizing radiation [e.g., X-ray and CT (computed tomography)] or radiotracers [e.g., positron emission tomography (PET) and single photon emission computed tomography (SPECT)] permitting long-term longitudinal studies. Since spatial resolution increases with magnetic field strength, the ability to track small cell populations has been realized.

MRI contrast agents are frequently utilized to permit the visual differentiation of cells and tissues that are magnetically similar but histologically distinct. Paramagnetic gadolinium-(III) complexes are the most widely used contrast agents, as Gd^{III} reduces the longitudinal relaxation time (T_1) of local water protons due to its high magnetic moment and symmetric S state. Areas enriched with Gd^{III} exhibit an increase in signal intensity and appear bright in T_1 -weighted images. Furthermore, chelation of the Gd^{III} ion (required to decrease latent toxicity) provides a means for chemical modification with targeting or bioactive moieties and cell transduction domains.

Recent advances in design and amplification strategies have produced a wide variety of bioactivatable contrast agents for investigating biologically important events such as ion fluctuation, enzyme activity, peroxide evolution, and temperature variation.^[5–12] However, the majority of these agents are incapable of penetrating cells and therefore are of limited use in cell tracking experiments.

Recent results suggest that Gd^{III} contrast agents have shown promise in cell tracking and fate-mapping experiments. For example, tracking stem cells in adult rat brains post stroke and monitoring β -islet cell transplantation has demonstrated potential.^[13–15] However, there are few examples of MR probes with the essential characteristics of high Gd^{III} loading for enhanced contrast coupled with facile cell uptake and long-term cell retention. Herein, we report a multimodal, cell permeable, Gd^{III} enriched polyvalent DNA–gold nanoparticle conjugate (DNA–Gd^{III}@AuNP) for cellular MR imaging. This conjugate takes advantage of high cellular uptake, excellent stability, and high Gd^{III} loading of polyvalent DNA–AuNPs.^[16,17] These are properties not shared by all nanostructures and are a result of the dense loading of the oligonucleotides on the surface of the DNA–AuNPs and their ability to bind to proteins, which facilitates endocytosis.^[18,19] In addition to gene regulation, DNA–AuNPs have been used in detection systems for DNA, proteins, metal ions, small molecules, and intracellular siRNA.^[18,20–31]

These Gd^{III} enriched DNA–AuNP conjugates represent a new class of MR contrast agents with the capability of highly efficient cell penetration and accumulation that provides sufficient contrast enhancement for imaging small cell populations with μ M Gd^{III} incubation concentrations. Moreover, these conjugates are labeled with a fluorescent dye permitting multimodal imaging to confirm cell uptake and intracellular accumulation, and providing a means for histological validation.^[32]

NP conjugates were prepared by reacting citrate-stabilized gold nanoparticles with thiol-labeled 24-mer poly-dT oligonucleotides. DNA oligomers were synthesized on a solid support with post-modification carried out in solution. The poly-dT contained five conjugation sites (hexylamino labeled dT groups conjugated with a cross linker, azidobutyrate- N -hydroxysuccinimide) for covalently attaching Gd^{III} complexes through click chemistry. Click chemistry has proven to be an efficient method for preparing Gd^{III}-based MR contrast agents with high synthetic yields and increased relaxivity.^[33]

After purification by RP-HPLC, the DNA–Gd^{III} conjugates were characterized by MALDI-MS, which confirmed formation of the conjugates. The DNA–Gd^{III} conjugates were then immobilized on citrate-stabilized AuNPs following literature procedures used to make the analogous Gd^{III}-free NPs to yield DNA–Gd^{III}@AuNPs (Scheme 1).^[34] Excess DNA–Gd^{III} was removed by repeated centrifugation and resuspension of the NPs until the supernatant was free of Gd^{III}. When suspended in aqueous solution, the NP conjugates appear deep red due to the plasmon resonance of the Au at 520 nm, and they are stable for months at room temperature


[*] Y. Song,^[‡] X. Xu,^[‡] K. W. MacRenaris, Prof. C. A. Mirkin, Prof. T. J. Meade
Department of Chemistry and International Institute for Nanotechnology, Northwestern University
2145 Sheridan Road, Evanston, IL 60208-3113 (USA)
Fax: (1) 847-491-3832
Fax: (1) 847-467-5123
E-mail: chadnano@northwestern.edu
tmeade@northwestern.edu

Dr. X.-Q. Zhang
Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208 (USA)

[†] These authors contributed equally to this work.

[**] We acknowledge financial support of the NCI/CCNE grant no. CA119341 and NIH grant no. R01EB005866. We thank E. Alex Waters for help with the 3T solution phantom images.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.200904666>.



Scheme 1. Synthesis of Cy3-DNA-Gd^{III}@AuNP conjugates.

(see Supporting Information). Cy3-labeled DNA oligomers were synthesized in order to produce Cy3-DNA-Gd^{III}@AuNPs for fluorescence microscopy and flow cytometry to confirm cell uptake and labeling efficiency, respectively.

The relaxation efficiency of these newly synthesized MR contrast agent conjugates were determined by taking the slope of a plot of the measured $1/T_1$ as a function of Gd^{III} concentration. The resultant relaxivity, r_1 , of the Gd^{III} complex after conjugation to DNA was determined to be $8.7 \text{ mm}^{-1} \text{ s}^{-1}$ at 37°C in water at 60 MHz (1.41 T). This represents a twofold increase over the unconjugated Gd^{III} complex ($3.2 \text{ mm}^{-1} \text{ s}^{-1}$, Table 1). This doubling in relaxivity is consistent with Solomon-Bloomberg-Morgan theory where decreases in rotational correlation time, τ_r , result in increases in r_1 .^[1,19]

Table 1: Relaxivities (r_1 s) of Gd^{III} complexes and conjugates at 60 MHz and 600 MHz.

	$r_1 [\text{mm}^{-1} \text{ s}^{-1}]$	
	60 MHz (1.41 T) ^[a]	600 MHz (14.1 T) ^[b]
DOTA-Gd ^{III}	3.2 ^[c]	2.2
DNA-Gd ^{III}	8.7	NM
13 nm DNA-Gd ^{III} @AuNP/ionic	16.9	5.1
13 nm DNA-Gd ^{III} @AuNP/particle	5779	1275
30 nm DNA-Gd ^{III} @AuNP/ionic	20.0	NM
30 nm DNA-Gd ^{III} @AuNP/particle	13 120	NM

[a] Measured in pure water at 37°C . [b] Measured in cell media at 25°C . [c] Data taken from ref. [1]. NM = not measured.

It is important to note that the relaxivity of Gd^{III} increases further when DNA-Gd^{III} is immobilized on the surface of AuNPs through gold-thiol linkages. We have examined two different sizes of AuNPs (13 and 30 nm) and found that the ionic relaxivity (per Gd^{III}) was $16.9 \text{ mm}^{-1} \text{ s}^{-1}$ for 13 nm DNA-Gd^{III}@AuNPs and $20.0 \text{ mm}^{-1} \text{ s}^{-1}$ for 30 nm DNA-Gd^{III}@AuNPs.

The degree of conjugation of chelates to the AuNP surface, was determined by calculating the Gd^{III} to Au ratio following ICP-MS where 13 nm DNA-Gd^{III}@AuNPs have 342 ± 1 Gd^{III} per NP and 30 nm DNA-Gd^{III}@AuNPs have 656 ± 20 Gd^{III} per NP. These calculations are based on the

assumption that there are 67 500 Au atoms per 13 nm AuNP, and 800 589 Au atoms per 30 nm AuNP (numbers were determined by geometric arguments and the crystal structure of bulk gold). Taking into account the loading of Gd^{III} per particle, the 13 nm DNA-Gd^{III}@AuNPs exhibited a relaxivity of approximately $5779 \text{ mm}^{-1} \text{ s}^{-1}$ per particle.

Previously, three research groups have shown increased relaxivities of Gd^{III} complexes by attaching thiol-derivatized Gd^{III} chelates on AuNPs.^[35,36] Moriggi et al. reported the highest relaxivity, namely $50 \text{ mm}^{-1} \text{ s}^{-1}$ (per Gd^{III}) at 60 MHz and 25°C . The higher relaxivity of this conjugate is a result of two water molecules (as opposed to one) coordinated to each Gd^{III} ion, and the increased rigidity due to the nature of the attachment of the chelates to the particle surface.^[36]

T_1 -weighted MR images of the DNA-Gd^{III}@AuNPs in solution phantoms were acquired at 3 T and 14.1 T at 25°C (see Supporting Information). The images clearly show that at each concentration [60, 40, 20 μM Gd^{III}], DNA-Gd^{III}@AuNPs appear significantly brighter than DOTA-Gd^{III} (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate) samples at the same concentration at both field strengths. T_1 analysis at 14.1 T reveals a 52 % reduction in T_1 for DNA-Gd^{III}@AuNPs (60 μM Gd^{III}) versus a 31 % reduction for DOTA-Gd^{III}. The image-based r_1 (at 14.1 T) of DNA-Gd^{III}@AuNP is $5.1 \text{ mm}^{-1} \text{ s}^{-1}$ whereas the r_1 of DOTA-Gd^{III} is $2.1 \text{ mm}^{-1} \text{ s}^{-1}$ (Table 1).

To determine the efficacy of cellular uptake, NIH/3T3 and HeLa cells were labeled with increasing concentrations of DNA-Gd^{III}@AuNPs or DOTA-Gd^{III} for different amounts of time. Following contrast agent incubation, cells were rinsed with DPBS (Dulbecco's phosphate buffered saline), counted, and then percent viability was assessed by flow cytometry. Gd^{III} and Au content were determined by ICP-MS of acid-digested samples. The cellular uptake of DNA-Gd^{III}@AuNPs was both time- and concentration-dependent (Figures 1 and 2). At all concentrations the Gd^{III} uptake was more than 50-fold higher for DNA-Gd^{III}@AuNPs compared to DOTA-




Figure 1. Time dependent cellular uptake of DNA-Gd^{III}@AuNPs compared to DOTA-Gd^{III} in NIH/3T3 and HeLa cells. Cells were incubated with $6.5 \mu\text{M}$ Gd^{III} for both contrast agents. Error bars represent ± 1 standard deviation of the mean for duplicate experiments.




Figure 2. Concentration dependent cellular uptake of DNA-Gd^{III}@AuNPs compared to DOTA-Gd^{III} in NIH/3T3 and HeLa cells. Cells were incubated for 24 h for both contrast agents. Error bars represent ± 1 standard deviation of the mean for duplicate experiments.

Gd^{III}. On average, cells take up 10^6 – 10^7 Gd^{III} ions per cell using only μM Gd^{III} incubation concentrations.^[37] Previous reports have suggested that at least 10^7 – 10^9 Gd^{III} ions per cell are necessary to produce detectable contrast enhancement.^[38] These reports, however, used mM incubation concentrations of Gd^{III} to reach that detection threshold due to the limited cellular uptake (lower transduction efficiency) and low relaxivity of the clinical agents used. Furthermore, compared with previous cell-permeable contrast agents using either the small transduction molecule stilbene and oligomeric poly-arginine-conjugated DOTA-Gd^{III}, the DNA-Gd^{III}@AuNP system exhibits the highest cellular uptake.^[39]

To demonstrate that μM Gd^{III} incubation concentrations of DNA-Gd^{III}@AuNP conjugates were sufficient to produce significant T_1 -weighted contrast enhancement of small cell populations, cells were labeled and imaged at 14.1 T. Specifically, NIH/3T3 cells were incubated with 5.0 μM or 20 μM (Gd^{III} concentration) of DOTA-Gd^{III} or DNA-Gd^{III}@AuNP for 24 h. T_1 -weighted MR images of cell pellets were acquired in 1.0 mm diameter glass capillaries, each containing approximately 10^6 cells (Figure 3). T_1 analysis revealed a 43 % and 29 % T_1 reduction with 20 μM and 5.0 μM DNA-Gd^{III}@AuNP




Figure 3. T_1 -weighted MR image of NIH/3T3 cells incubated with 20 μM and 5.0 μM (Gd^{III} concentrations) DNA-Gd^{III}@AuNP and DOTA-Gd^{III} for 24 h at 14.1 T (600 MHz) and 25 °C. Echo time (TE) = 10.2 ms, repetition time (TR) = 750 ms, field of view (FOV) = $10 \times 10 \text{ mm}^2$, slice thickness = 1.0 mm.

labeled cell pellets, respectively. Cell pellets incubated with DOTA-Gd^{III} at either concentration showed no significant difference from control cell pellets. To our knowledge, these results represent the lowest reported incubation concentration of a Gd^{III} complex or conjugate to produce a greater than 40 % reduction of T_1 in cell pellets (see Supporting Information).^[40]

For comparison, MRI has been applied to tracking Gd^{III} labeled β -islets for transplantation and stem cell migration with DO3AHP-Gd^{III} with incubation concentrations ranging from 20–50 mM.^[41] We are reporting a 1000-fold decrease in Gd^{III} incubation concentration to obtain essentially the same contrast enhancement. We have found that efficient delivery and accumulation of Gd^{III} complexes is critical for improving the detection limit for high resolution cellular imaging at high magnetic field.

The DNA-Gd^{III}@AuNP conjugates are resistant to nuclease degradation which is important for long term cell tracking.^[14] We have determined (by ICP-MS) that the ratio of Au to Gd^{III}, after cell internalization, remains constant for at least 24 h. This implies that the DNA-Gd^{III}@AuNP assembly did not undergo enzyme digestion over this time period which is consistent with previously published results using similar DNA-AuNP conjugates.^[42]

To confirm the intracellular accumulation and uptake efficiency of the DNA-Gd^{III}@AuNPs, bimodal AuNP conjugates were synthesized by conjugating Cy3 to the 5' end of the DNA-Gd^{III} strands. The ratio of optical to MR signal can be adjusted by altering the stoichiometry of the Cy3-labeled DNA-Gd^{III} strands with non-labeled strands. Specifically, NIH/3T3 and HeLa cells were labeled with 0.1–0.2 nM Cy3-DNA-Gd^{III}@AuNPs for 24 h, rinsed three times with DPBS, and imaged using a confocal laser scanning microscope (CLSM).

The fluorescence micrographs show that the Cy3-DNA-Gd^{III}@AuNPs localize in small vesicles in the perinuclear region, which is consistent with previous reports that show AuNP conjugates are taken up through an endocytic mechanism (Figure 4).^[43] A second batch of cells was incubated under the same conditions and allowed to leach for 24 h (media with contrast agent is replaced with fresh media after




Figure 4. Confocal fluorescence micrographs of NIH/3T3 cells incubated with 0.2 nM particle concentration of Cy3-DNA-Gd^{III}@AuNPs for 4.0 h and a 24 h leach in fresh media and 1 μM DAPI (4',6-diamidino-2-phenylindole) for 10 min. Left: merge of the blue (DAPI) and red (Cy3-DNA-Gd^{III}@AuNPs) channels; Right: overlay, with transmitted light image. Scale bar = 50 μm .

rinsing). During this time the cell number doubled, but the fluorescence signal persisted in essentially every cell.

Cell labeling efficiency was evaluated using analytical flow cytometry and showed that at 0.3 nM Cy3-DNA-Gd^{III}@AuNP incubation concentration, 80 % of the cells were labeled after 4.0 h. In both NIH/3T3 and HeLa cells, labeling reached 100 % after a 24 h incubation (see Supporting Information). Importantly, we did not observe any evidence of cell toxicity or cell number variation under any of the conditions tested using DNA-Gd^{III}@AuNPs or DOTA-Gd^{III} (see Supporting Information).

In conclusion, we have demonstrated a new multimodal, cell permeable MR contrast agent based upon polyvalent DNA-AuNPs. These particles exhibit excellent biocompatibility and stability, high Gd^{III} loading, a greater than 50-fold increase in cell uptake compared to the clinically available contrast agent DOTA-Gd^{III}, and relatively high relaxivity. Work is underway to investigate the utility of these agents for in vivo applications regarding cell tracking in animal models. A primary goal of these studies will be to determine the minimum number of cells that can be detected by this approach.

When modified with a fluorophore, the DNA-Gd^{III}@AuNPs can be used as multimodal imaging agents where fluorescence microscopy showed that the particles localize in the perinuclear region inside cells. Since AuNPs serve as CT contrast agents, these DNA-Gd^{III}@AuNP conjugates have promise as multimodal imaging probes for MR, fluorescence, and CT. The library of available probes for cancer and biological cellular imaging is growing and the strategy presented in this work represents a promising new addition.^[20,44–47]

Received: August 21, 2009

Published online: October 30, 2009

Keywords: DNA · fluorescence imaging · gadolinium · gold nanoparticles · magnetic resonance imaging

- [1] *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*, (Eds.: A. E. Merbach, E. Toth), Wiley, New York, **2001**.
- [2] S. Aime, C. Cabella, S. Colombatto, S. Geninatti Crich, E. Gianolio, F. Maggioni, *J. Magn. Reson. Imaging* **2002**, *16*, 394.
- [3] X. Hu, D. G. Norris, *Annu. Rev. Biomed. Eng.* **2004**, *6*, 157.
- [4] P. M. Winter, S. D. Caruthers, S. A. Wickline, G. M. Lanza, *Curr. Cardiol. Rep.* **2006**, *8*, 65.
- [5] P. Caravan, *Chem. Soc. Rev.* **2006**, *35*, 512.
- [6] J. L. Major, T. J. Meade, *Acc. Chem. Res.* **2009**, *42*, 893.
- [7] S. Aime, D. Delli Castelli, S. Geninatti Crich, E. Gianolio, E. Terreno, *Acc. Chem. Res.* **2009**, *42*, 822.
- [8] J. A. Duimstra, F. J. Femia, T. J. Meade, *J. Am. Chem. Soc.* **2005**, *127*, 12847.
- [9] J. L. Major, G. Parigi, C. Luchinat, T. J. Meade, *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 13881.
- [10] W.-h. Li, S. E. Fraser, T. J. Meade, *J. Am. Chem. Soc.* **1999**, *121*, 1413.
- [11] P. Caravan, N. J. Cloutier, M. T. Greenfield, S. A. McDermid, S. U. Dunham, J. W. M. Bulte, J. C. Amedio, Jr., R. J. Looby, R. M. Supkowski, W. DeW. Horrocks, Jr., T. J. McMurphy, R. B. Lauffer, *J. Am. Chem. Soc.* **2002**, *124*, 3152.
- [12] F. K. Kalman, M. Woods, P. Caravan, P. Jurek, M. Spiller, G. Tircso, R. Kiraly, E. Bruecher, A. D. Sherry, *Inorg. Chem.* **2007**, *46*, 5260.
- [13] M. Modo, K. Mellodew, D. Cash, S. E. Fraser, T. J. Meade, J. Price, S. C. R. Williams, *Neuroimage* **2004**, *21*, 311.
- [14] *Molecular and Cellular MR Imaging* (Eds.: M. Modo, J. W. Bulte), CRC, Boca Raton, **2007**.
- [15] L. Biancone, G. C. Simonetta, V. Cantaluppi, M. R. Giuseppe, S. Russo, E. Scalabrino, G. Esposito, F. Figliolini, S. Beltramo, C. P. Paolo, P. S. Giuseppe, S. Aime, G. Camussi, *NMR Biomed.* **2007**, *20*, 40.
- [16] N. L. Rosi, D. A. Giljohann, C. S. Thaxton, A. K. R. Lytton-Jean, M. S. Han, C. A. Mirkin, *Science* **2006**, *312*, 1027.
- [17] D. S. Seferos, A. E. Prigodich, D. A. Giljohann, P. C. Patel, C. A. Mirkin, *Nano Lett.* **2009**, *9*, 308.
- [18] N. L. Rosi, C. A. Mirkin, *Chem. Rev.* **2005**, *105*, 1547.
- [19] D. A. Giljohann, D. S. Seferos, P. C. Patel, J. E. Millstone, N. L. Rosi, C. A. Mirkin, *Nano Lett.* **2007**, *7*, 3818.
- [20] C. A. Mirkin, R. L. Letsinger, R. C. Mucic, J. J. Storhoff, *Nature* **1996**, *382*, 607.
- [21] R. Elghanian, J. J. Storhoff, R. C. Mucic, R. L. Letsinger, C. A. Mirkin, *Science* **1997**, *277*, 1078.
- [22] T. A. Taton, C. A. Mirkin, R. L. Letsinger, *Science* **2000**, *289*, 1757.
- [23] Y. C. Cao, R. Jin, J.-M. Nam, C. S. Thaxton, C. A. Mirkin, *J. Am. Chem. Soc.* **2003**, *125*, 14676.
- [24] M. S. Han, A. K. R. Lytton-Jean, C. A. Mirkin, *J. Am. Chem. Soc.* **2006**, *128*, 4954.
- [25] J.-S. Lee, M. S. Han, C. A. Mirkin, *Angew. Chem.* **2007**, *119*, 4171; *Angew. Chem. Int. Ed.* **2007**, *46*, 4093.
- [26] X. Xu, M. S. Han, C. A. Mirkin, *Angew. Chem.* **2007**, *119*, 3538; *Angew. Chem. Int. Ed.* **2007**, *46*, 3468.
- [27] X. Xu, D. G. Georganopoulos, H. D. Hill, C. A. Mirkin, *Anal. Chem.* **2007**, *79*, 6650.
- [28] D. A. Giljohann, D. S. Seferos, A. E. Prigodich, P. C. Patel, C. A. Mirkin, *J. Am. Chem. Soc.* **2009**, *131*, 2072.
- [29] J. M. C. Bowman, E. T. Ballard, C. J. Ackerson, J. D'Antonio, D. L. Feldheim, D. Margolis, C. Melander, *J. Am. Chem. Soc.* **2008**, *130*, 6896.
- [30] J. Liu, Y. Lu, *Angew. Chem.* **2007**, *119*, 7731; *Angew. Chem. Int. Ed.* **2007**, *46*, 7587.
- [31] S. S. Agasti, A. Chompoosor, C.-C. You, P. Ghosh, C. K. Kim, V. M. Rotello, *J. Am. Chem. Soc.* **2009**, *131*, 5728.
- [32] L. Frullano, T. J. Meade, *J. Biol. Inorg. Chem.* **2007**, *12*, 939.
- [33] Y. Song, E. K. Kohlmeier, T. J. Meade, *J. Am. Chem. Soc.* **2008**, *130*, 6662.
- [34] J. J. Storhoff, R. Elghanian, R. C. Mucic, C. A. Mirkin, R. L. Letsinger, *J. Am. Chem. Soc.* **1998**, *120*, 1959.
- [35] a) J.-A. Park, P. A. N. Reddy, H.-K. Kim, I.-S. Kim, G.-C. Kim, Y. Chang, T.-J. Kim, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 6135; b) P.-J. Deboutiere, S. Roux, F. Vocanson, C. Billotey, O. Beuf, A. Favre-Reguillon, Y. Lin, S. Pellet-Rostaing, R. Lamartine, P. Perriat, O. Tillement, *Adv. Funct. Mater.* **2006**, *16*, 2330; c) C. Alric, J. Taleb, G. Le Duc, C. Mandon, C. Billotey, A. Le Meur-Herland, T. Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux, O. Tillement, *J. Am. Chem. Soc.* **2008**, *130*, 5908.
- [36] L. Moriggi, C. Cannizzo, E. Dumas, C. R. Mayer, A. Ulianov, L. Helm, *J. Am. Chem. Soc.* **2009**, *131*, 10828.
- [37] Note that on average the cells internalize approximately 10⁵ Gd^{III} conjugates/cell, which is two orders of magnitude higher than citrate-stabilized AuNPs of the same size.
- [38] The nanoparticle concentration is over two orders of magnitude lower since each particle contains approximately 50 strands of DNA-Gd conjugates.
- [39] a) M. J. Allen, K. W. MacRenaris, P. N. Venkatasubramanian, T. J. Meade, *Chem. Biol.* **2004**, *11*, 301; b) P. J. Endres, K. W.

- MacRenaris, S. Vogt, M. J. Allen, T. J. Meade, *Mol. Imaging* **2006**, 5, 485.
- [40] L. Biancone, S. G. Crich, V. Cantaluppi, G. M. Romanazzi, S. Russo, E. Scalabrino, G. Esposito, F. Figliolini, S. Beltramo, P. C. Perin, G. P. Segoloni, S. Aime, G. Camussi, *NMR Biomed.* **2007**, 20, 40.
- [41] S. G. Crich, L. Biancone, V. Cantaluppi, D. Duo, G. Esposito, S. Russo, G. Camusi, S. Aime, *Magn. Reson. Med.* **2004**, 51, 938.
- [42] D. S. Seferos, A. E. Prigodich, D. A. Giljohann, P. C. Patel, C. A. Mirkin, *Nano Lett.* **2009**, 9, 308.
- [43] B. D. Chithrani, W. C. W. Chan, *Nano Lett.* **2007**, 7, 1542.
- [44] A. M. Smith, H. Duan, A. M. Mohs, S. Nie, *Adv. Drug Delivery Rev.* **2008**, 60, 1226.
- [45] P. Alivisatos, *Nat. Biotechnol.* **2004**, 22, 47.
- [46] Y. N. Xia, *Nat. Mater.* **2008**, 7, 758.
- [47] B. Y. S. Kim, W. Jiang, J. Oreopoulos, C. M. Yip, J. T. Rutka, W. C. W. Chan, *Nano Lett.* **2008**, 8, 3887.
-